These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30846724)

  • 1. Bcl-x
    Rello-Varona S; Fuentes-Guirado M; López-Alemany R; Contreras-Pérez A; Mulet-Margalef N; García-Monclús S; Tirado OM; García Del Muro X
    Sci Rep; 2019 Mar; 9(1):3816. PubMed ID: 30846724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
    Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
    Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
    Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
    PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway.
    Zhao H; Li S; Wang G; Zhao W; Zhang D; Wang F; Li W; Sun L
    Cancer Med; 2019 Aug; 8(9):4348-4358. PubMed ID: 31207099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
    Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
    PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.
    Varadarajan S; Poornima P; Milani M; Gowda K; Amin S; Wang HG; Cohen GM
    Oncotarget; 2015 May; 6(14):12668-81. PubMed ID: 26059440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
    Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
    J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
    Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M
    PLoS One; 2013; 8(3):e59588. PubMed ID: 23527225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
    Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
    Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X
    Beltrán-Visiedo M; Jiménez-Alduán N; Díez R; Cuenca M; Benedi A; Serrano-Del Valle A; Azaceta G; Palomera L; Peperzak V; Anel A; Naval J; Marzo I
    Mol Oncol; 2023 Dec; 17(12):2507-2525. PubMed ID: 37704591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
    Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
    J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
    Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
    Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
    Moharram SA; Shah K; Khanum F; Marhäll A; Gazi M; Kazi JU
    Cancer Lett; 2017 Oct; 405():73-78. PubMed ID: 28756008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
    Alsayegh K; Matsuura K; Sekine H; Shimizu T
    Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.